In a nutshell This study compared the effectiveness and safety between immune checkpoint inhibitors (ICIs) and docetaxel (Taxotere) therapy alone in patients with non-small cell lung cancer (NSCLC). The data showed ICIs significantly improved the survival outcomes with fewer serious side effects compared to docetaxel alone for the treatment of patients...
Read MoreComparing the effectiveness and safety between immune checkpoint inhibitors and docetaxel in patients with non-small cell lung cancer.
